Real-life Experience With AcrySof® IQ Vivity® Intraocular Lens Implant: Functional Outcomes and Quality of Life

Abstract

Abstract Purpose The extended depth-of-focus AcrySof® IQ Vivity® intraocular lens technology offers promising features for presbyopia management, evaluated in this research in a 6 months real-world setting. Methods Prospective interventional mono-centric study including 40 patients who underwent elective bilateral phacoemulsification. We performed one pre-operative visit (V0) and one evaluation six months post-operatively, evaluating uncorrected and corrected visual acuity for near (UNVA/CNVA), intermediate (UIVA/CIVA) and far (UDVA/UCVA), slit-lamp evaluation, tomography with dynamic pupillometry, endothelial cell count and contrast sensitivity chart. In order to assess post-operative Quality of Life, we administered the patients McAlinden's Quality of Vision test and Morlock's Patient-Reported Spectacle Independence Questionnaire. Results Mean UDVA significantly improved to 0,04 ± 0,06 LogMar (p = 0.0001), while binocular UDVA was 0,00 ± 0,03 LogMar. For intermediate vision, binocular UIVA was 0.20 ± 0.10 LogMar at 80 cm and 0.30 ± 0.16 LogMar at 60 cm. At 40 cm, monocular and binocular UNVA were 0.52 ± 0.19 LogMar and 0.41 ± 0.16 LogMAR, respectively. Sixty-percent of eyes reached 0,00 LogMar for near vision with an addition of 1,00 D. Overall, 38 (95%) patients had a mean contrast sensitivity value ≥ 1,7 log. Twenty-one (53%) patients reported total independence from their glasses at all distances. The mean difference between the predicted and actual refractive error, as calculated by spherical equivalent, was 0,09 D. Conclusions AcrySof® IQ Vivity® is a well-tolerated and effective IOL with optimal refractive target for both distant and intermediate vision, needing slight spherical addition for the best near vision. Great questionnaire-based satisfaction was reported by the patients.